2011

Senate Bill 486 Evaluation Team
CONSUMER REPORT CARD

SUMMARY:

The legislatively mandated deadline for report submission was July 1, 2011. There were 24 plans submitted as of July 5th to the State of California which posted them on their website for public consumption. These plans were read and graded by a 9-person evaluation team, scoring each plan based on published consumer criteria. There were:

- Three "A" grade plans;
- One "B" grade plan;
- One "C" grade plan;
- Two "D" grade plans;
- Sixteen "F" grade plans.
- In addition, Fifteen "F/Incomplete" grade plans were given for those manufacturers who did not submit plans by the legislatively mandated deadline of July 1 or did not submit plans whatsoever.
- Two "Honorable Mentions"
- NOTE: At least five manufacturers resubmitted their 2010 plans verbatim and those are indicated with an asterisk(*).

Manufacturer	Score	Grade
Abbott Laboratories	94	A
Amgen*	62	D-
Amylin	18	F
Baxter	2	F
Biogen Idec	11	F
Bristol Meyers Squibb	73	C
CSL Behring*	2	F
Eisai	62	D
Eli Lilly & Co.	13	F
EMD Serono	88	B+
Ferring Pharmaceuticals	15	F
Genentech/Roche (Note: their 2010 grade was a C)	46	F
GlaxoSmithKline	53	F
Janssen Biotech, Inc./ Johnson & Johnson	94	A
Merck & Co.*(Including Schering Corp.)	32	F
Novartis	4	F
Novo Nordisk	13	F
Pfizer	26	F
Sandoz	8	F
Sanofi-Aventis	47	F
Teva Biologics*	18	F
Teva Neuroscience*	22	F
UCB, Inc.	94	A

HONORABLE MENTION:

- **BD (Becton, Dickinson and Co.)**
- **Waste Management, Inc.**

Although they weren't subject to SB 486, they submitted a plan and earned an **honorable mention** from the SB 486 Evaluation Committee.

The following drug manufactures earned an automatic F grade based on the incomplete nature of their reports. Those manufacturers are:

IN VIOLATION OF STATE LAW DUE TO THE FACT THAT THEY **DID NOT SUBMIT** ANY PLANS TO THE STATE.

Manufacturer	**Grade**
Bayer	F/Incomplete
Biovitrium (2nd year in a row of non-compliance)	F/Incomplete
Hoffmand LaRoche (2nd year in a row of non-compliance)	F/Incomplete
Questcor Pharmaceuticals (2nd year in a row of non-compliance)	F/Incomplete
Zoegenix (2nd year in a row of non-compliance)	F/Incomplete
Dr. Reddy's Laboratories, Inc.	F/Incomplete
Fresenius Medical Care	F/Incomplete

IN VIOLATION OF STATE LAW DUE TO THE FACT THAT THEY **SUBMITTED** PLANS TO THE STATE **AFTER LEGISLATIVELY MANDATED JULY 1ST DEADLINE.**

Manufacturer	**Grade**
Dey Pharma (Submitted July 10, 2011. Submitted late in 2010 also: August 18, 2010)	F/Incomplete
Grifols, Inc. (Submitted July 20, 2011)	F/Incomplete
Hospira (Submitted August 10, 2011)	F/Incomplete
InterMune (Submitted August 23, 2011)	F/Incomplete
Ipsen (Submitted September 1, 2011. Did not submit a plan in 2010.)	F/Incomplete
Kadmon Pharmaceuticals (formerly Three Rivers Pharma) (Submitted August 2, 2011. Three Rivers submitted late in 2010 also: October 1, 2010)	F/Incomplete
Novartis (Submitted November 15, 2011)	F/Incomplete
Perrigo (Submitted November 15, 2011)	F/Incomplete
Salix Pharmaceuticals (Submitted August 3, 2011)	F/Incomplete
Shinogi, Inc. (Submitted August 15, 2011. Submitted late in 2010 also: August 19, 2010)	F/Incomplete
ViroPharma (Submitted September 22, 2011)	F/Incomplete